Chinese government okays Sumitomo investment
After 16 months of wrangling, Japanese investor secures 20% in Henan Topfond Pharmaceutical.
Sumitomo, one of JapanÆs largest trading corporations, announced yesterday March 13 that it has completed the acquisition of a strategic interest in a profitable Chinese drug-maker. The deal will enable Sumitomo, which also recently acquired a Japanese drug maker, to expand its presence in China, and to source Henan TopfondÆs range of generic drugs for sales abroad.
The deal represents the first such strategic stake in a Chinese company by Sumitomo, which has previously been restricted to joint ventures. Although...
To continue reading, please login or register for free